Pim1 inhibitor for treating myeloproliferative neoplasms
AssigneeSumitomo Pharma America, Inc.
InventorsEmily M. Brooks, Jason M. Foulks, Sujan Kabir, Claudia A. Lebedinsky, Jian Mei, Mark L. Wade, Clifford J. Whatcott
Life of this patent
Estimating the term…
Abstract
Methods for treatment of myeloproliferative neoplasms are provided, particularly in patients with poor bone marrow functioning, and difficult to treat human patients such as those with relapsed or refractory disease. The disclosed methods comprise administering Compound (1) having the following structure: or a pharmaceutically acceptable salt thereof, and optionally a JAK kinase inhibitor and/or ACVR inhibitor, to a human subject in need thereof.
Claims33
A method for treating a myeloproliferative neoplasm in a human subject in need thereof, comprising administering to the subject a therapeutically effective amount of compound (1):
- or a pharmaceutically acceptable salt thereof,
- wherein the subject has poor bone marrow functioning characterized by:
- (i) thrombocytopenia;
- (ii) anemia;
- (iii) transfusion dependence;
- or
- (iv) a combination thereof;
- and wherein the treatment induces a clinically meaningful response in the subject.
2-3. (canceled)
A method of treating a myeloproliferative neoplasm by inducing:
- (a) TSS50 in a human subject in need thereof;
- (b) a probability of SVR20 in a human subject affected by the myeloproliferative neoplasm about ≥15%;
- or
- (c) a combination of (a) and (b),
- the method comprising administering to the subject a therapeutically effective amount of compound (1):
- or a pharmaceutically acceptable salt thereof,
- wherein the myeloproliferative neoplasm is treated by inducing TSS50 in the subject, the treatment induces a probability of SVR20 in the subject about ≥15%, or a combination thereof.
5-6. (canceled)
(canceled)
11-15. (canceled)
(canceled)
19-24. (canceled)
26-27. (canceled)
29-31. (canceled)
34-35. (canceled)
(canceled)
41-42. (canceled)
A method of treating a myeloproliferative neoplasm by inducing:
- (a) TSS50 in a human subject in need thereof;
- (b) a probability of SVR20 in the human subject affected by the myeloproliferative neoplasm about ≥15%;
- or
- (c) a combination of (a) and (b),
- the method comprising administering to the subject a therapeutically effective amount of compound (1):
- or a pharmaceutically acceptable salt thereof and optionally momelotinib or a pharmaceutically acceptable salt thereof,
- wherein:
- the myeloproliferative neoplasm is treated by inducing TSS50 in the subject, the treatment induces a probability of SVR20 in the subject about ≥15%, or a combination thereof, and
- the subject has poor bone marrow functioning characterized by:
- (i) thrombocytopenia;
- (ii) anemia;
- (iv) transfusion dependence;
- or
- (v) a combination thereof.
Dependencies are inferred from the claim text.